Skip to search formSkip to main contentSkip to account menu

NT 201

Known as: NT-201, NT201 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

incobotulinumtoxinA

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
High Dose of Botulinum Toxin Type A (NT-201) for the Treatment of Dysphagia due to Severe Spasticity of Upper Oesophageal Sphincter: ACase Report
Background: Botulinum toxin type A (BoNT-A) has been used in treating dysphagia due to spasticity of upper oesophageal sphincter… 
2014
2014
High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
BACKGROUND Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A… 
2014
2014
Incobotulinum booster injections in patients with spasticity and dystonia after stroke
2014
2014
Efficacy of incobotulinum toxin A (Xeomin®) in the treatment of dynamic equinus foot in children with hemiplegic cerebral palsy
Review
2012
Review
2012
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including… 
2012
2012
Treatment of Upper Limb Spasticity after Stroke: One-Year Safety and Efficacy of Botulinum Toxin Type A NT201
A new preparation of botulinum toxin type A called NT 201, free from complexing proteins, potentially with low antigenicity has… 
Highly Cited
2009
Highly Cited
2009
Relationship between various clinical outcome assessments in patients with blepharospasm
The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self‐rating patient response outcome… 
2009
2009
FP50-TH-06 Efficacy and safety of NT 201 (Xeomin®, botulinum neurotoxin free from complexing proteins) in cervical dystonia
2008
2008
NT201 (Xeomin) in upper limb post-stroke spasticity: results of a double-blind, placebo-controlled, randomised, multi-centre trial
2008
2008
Clinical safety of NT 201 (Xeomin®): A meta-analysis
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)